[
    [
        {
            "time": "",
            "original_text": "沃森生物去年净利10亿同比增长295% 董事长李云春薪酬101万元",
            "features": {
                "keywords": [
                    "沃森生物",
                    "净利润",
                    "同比增长",
                    "295%",
                    "董事长",
                    "李云春",
                    "薪酬"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "沃森生物去年净利10亿同比增长295% 董事长李云春薪酬101万元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【国盛医药张金洋团队】详解2019Q1机构医药持仓，继续推荐医药流通",
            "features": {
                "keywords": [
                    "国盛医药",
                    "张金洋",
                    "团队",
                    "2019Q1",
                    "机构持仓",
                    "医药流通"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药流通"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国盛医药张金洋团队】详解2019Q1机构医药持仓，继续推荐医药流通",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        }
    ]
]